Login to Your Account

Clinic Roundup

Wednesday, January 2, 2013
• Synergy Pharmaceuticals Inc., of New York, completed a Phase I single-ascending dose trial of SP-333 for ulcerative colitis and other gastrointestinal diseases. The placebo-controlled, dose-escalating trial assessed safety and pharmacodynamics in eight volunteer cohorts, dosed from 0.1 mg to 60 mg.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription